Characteristic | No. of patients (%) |
---|---|
Age (years) | |
 ≤ 60 | 37 (82.2) |
 > 60 | 8 (17.8) |
Gender | |
 Male | 25 (55.6) |
 Female | 20 (44.4) |
CEA (mg/mL) | |
 < 5.00 | 28 (62.2) |
 ≥ 5.00 | 17 (37.8) |
CA19-9 (μg/mL) | |
 < 27 | 31 (68.9) |
 ≥ 27 | 14 (31.1) |
Clinical T category | |
 T2 | 1 (2.2) |
 T3 | 18 (40.0) |
 T4a | 21 (46.7) |
 T4b | 5 (11.1) |
Clinical N category | |
 N0 | 5 (11.1) |
 N1 | 15 (33.3) |
 N2 | 25 (55.6) |
Clinical disease category | |
 Stage II | 5 (11.1) |
 Stage III | |
  IIIA | 1 (2.2) |
  IIIB | 12 (26.7) |
  IIIC | 27 (60) |
Location from anal verge (cm) | |
 0–5 | 27 (60.0) |
 > 5–10 | 15 (33.3) |
 > 10 | 3 (6.7) |
Tumor differentiation | |
 Well differentiated (G1) | 2 (4.4) |
 Moderately differentiated (G2) | 28 (62.2) |
 Poor differentiated (G3) | 5 (11.1) |
 Other or missing | 10 (22.2) |